Luca Gianni
Fondazione Michelangelo(IT)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer(2005)5,074 cited
- → Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis(2014)4,584 cited
- → Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer(2012)3,713 cited
- → Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity(2004)3,676 cited
- → Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease(2016)2,970 cited
- → Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial(2011)2,311 cited